claravis accutane using HER2 patient derived xenografts PDX, obtained and characterized TDM1 resistant cells, also unable of responding to lapatinib and afatinib, but with an acquired sensitivity to a covalent FGFR kinase inhibitor, strongly supporting therapeutic combination of TDM1 with FGFR inhibitors in HER2 BrCa treatment 100